Edgestream Partners, L.P. Cytokinetics Inc Transaction History
Edgestream Partners, L.P.
- $3.48 Billion
- Q2 2025
A detailed history of Edgestream Partners, L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 15,275 shares of CYTK stock, worth $906,571. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,275
Previous 18,216
16.15%
Holding current value
$906,571
Previous $732,000
31.15%
% of portfolio
0.01%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding CYTK
# of Institutions
385Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.04 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$871 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$711 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$465 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$378 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.59B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...